tbuckley/cabot-search huggingface dataset:
Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future
Authors: Razan Alzeibak, Tatiana A. Mishchenko, Natalia Y. Shilyagina, Irina V. Balalaeva, Maria V. Vedunova, Dmitri V. Krysko
Journal: Journal for ImmunoTherapy of Cancer (2021)

The past decade has witnessed major breakthroughs in cancer immunotherapy. This development has been largely motivated by cancer cell evasion of immunological control and consequent tumor resistance to conventional therapies. Immunogenic cell death (ICD) is considered one of the most promising ways to achieve total tumor cell elimination. It activates the T-cell adaptive immune response and results in the formation of long-term immunological memory. ICD can be triggered by many anticancer treatment modalities, including photodynamic therapy (PDT). In this review, we first discuss the role of PDT based on several classes of photosensitizers, including porphyrins and non-porphyrins, and critically evaluate their potential role in ICD induction. We emphasize the emerging trend of ICD induction by PDT in combination with nanotechnology, which represents third-generation photosensitizers and involves targeted induction of ICD by PDT. However, PDT also has some limitations, including the reduced efficiency of ICD induction in the hypoxic tumor microenvironment. Therefore, we critically evaluate strategies for overcoming this limitation, which is essential for increasing PDT efficiency. In the final part, we suggest several areas for future research for personalized cancer immunotherapy, including strategies based on oxygen-boosted PDT and nanoparticles. In conclusion, the insights from the last several years increasingly support the idea that PDT is a powerful strategy for inducing ICD in experimental cancer therapy. However, most studies have focused on mouse models, but it is necessary to validate this strategy in clinical settings, which will be a challenging research area in the future.
Potentiation of NETs release is novel characteristic of TREM-1 activation and the pharmacological inhibition of TREM-1 could prevent from the deleterious consequences of NETs release in sepsis
Authors: Amir Boufenzer, Kevin Carrasco, Lucie Jolly, Benjamin Brustolin, Elisa Di-Pillo, Marc Derive, Sébastien Gibot
Journal: Cellular and Molecular Immunology (2021)

Abstract During sepsis, neutrophil activation induces endothelial cell (EC) dysfunction partly through neutrophil extracellular trap (NET) release. The triggering receptor expressed on myeloid cell-1 (TREM-1) is an orphan immune receptor that amplifies the inflammatory response mediated by Toll-like receptor-4 (TLR4) engagement. Although the key role of TLR4 signaling in NETosis is known, the role of TREM-1 in this process has not yet been investigated. Here, we report that TREM-1 potentiates NET release by human and murine neutrophils and is a component of the NET structure. In contrast, pharmacologic inhibition or genetic ablation of TREM-1 decreased NETosis in vitro and during experimental septic shock in vivo. Moreover, isolated NETs were able to activate ECs and impair vascular reactivity, and these deleterious effects were dampened by TREM-1 inhibition. TREM-1 may, therefore, constitute a new therapeutic target to prevent NETosis and associated endothelial dysfunction.
Clinical and histopathologic predictors of therapeutic response to bronchial thermoplasty in severe refractory asthma
Authors: Maha Zohra Ladjemi, Leonarda Di Candia, Nicolas Heddebaut, Camille Techoueyres, Eloise Airaud, David Soussan, Marie-Christine Dombret, Fatima Hamidi, Noëlline Guillou, Pierre Mordant, Yves Castier, Séverine Létuvé, Camille Taillé, Michel Aubier, Marina Pretolani
Journal: Journal of Allergy and Clinical Immunology (2021)
Rapid induction of apoptosis by a Chinese herb compound, shikonin, via modulation of IL-6/STAT3- and IGF-I/IGF-I R-mediated dual survival pathways in human multiple myeloma cells
Authors: Takehiro Kimura, Tomonori Nakazato, Yasuo Ikeda, Masahiro Kizaki
Journal: Cancer Research (2005)

3080  Despite the use of high dose chemotherapy with hematopoietic stem cell transplantation, multiple myeloma remains still incurable hematological malignancy. Therefore, new biologically-based treatments are urgently needed in the clinical settings. New promising agents including thalidomide and bortezomib have been introduced for the treatment of refractory myeloma, but their long-term efficacy remains unclear. Shikonin is a naphthoquinone derivative extracted from a traditional Chinese medical herb, Lithospermum erythrorhizon. Shikonin has been found to posses a variety of biological activities including strong wound healing, anti-bacterial, anti-inflammatory, and anti-tumor effects. Recently, it has been reported that shikonin induces apoptosis of various cancer cells. However, the mechanisms responsible for these activities of shikonin are still unknown. In addition, there have been no studies concerned in the effects of shikonin on myeloma cells. In this study, we have investigated the effects of shikonin on cell proliferation, cell cycle progression and mechanism of apoptosis in various human myeloma cell lines and fresh myeloma cells from patients. Shikonin markedly suppressed the cellular growth of cell lines including U266, RPMI8226, IM9 and HS-sultan cells as well as fresh myeloma cells via induction of apoptosis in a dose (0-5 μM)- and time (0-24hrs)-dependent manner. Treatment with 0.5μM shikonin induced G1 cell cycle arrest in U266 and RPMI8226 cells with induction of cdk inhibitors, p21 and p27. Activation of caspase-9, caspase-8 and caspase-3, and cleavage of PARP was shown to take place in U266 and RPMI8226 cells, resulting in the fragmentation of genomic DNA of the cells. Shikonin induced up-regulation of pro-apoptotic protein Bax, and down-regulation of anti-apoptotic protein Mcl-1 in a time- and dose-dependent manner. Shikonin also induced the loss of mitochondrial transmembrane potential and release of mitochondrial cytochrome c into the cytosol. IL-6/STAT3 and IGF-I/IGF-IR are important signaling molecules for proliferation in myeloma cells. Shikonin markedly inhibited both IL-6-induced phosphorylation of STAT3 and IGF-I-induced phosphorylation of IGF-IR in myeloma cells. Shikonin also reduced phosphorylation of their downstream targets of Akt and FKHR. Moreover, shikonin was able to overcome the growth advantage conferred on myeloma cells by IL-6 and IGF-1. Furthermore, shikonin dramatically potentiated the anti-tumor effects of therapeutic drugs including adriamycin, melphalan and dexamethasone. Taken together, these results strongly indicate that the inhibition of cellular growth of myeloma cells by shikonin through the dual inhibition of IL-6/STAT3- and IGF-I/IGF-IR-mediated survival pathways has potential as a new therapeutic agent for the management of multiple myeloma.
Postexercise Ankle-Brachial Index Testing to Diagnose Peripheral Artery Disease—Reply
Authors: Anurag Mehta, Laurence S. Sperling, Bryan J. Wells
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MO01.20 Pembrolizumab+Chemo versus Atezolizumab+Chemo+/-Bevacizumab for First-Line Nonsquamous NSCLC: A Matching-Adjusted Indirect Comparison
Authors: B. Halmos, T. Burke, C. Kalyvas, K. Vandormael, A. Frederickson, B. Piperdi
Journal: Journal of Thoracic Oncology (2021)
Myocardial Perfusion Using Arterial Spin Labeling CMR: Promise and Challenges⁎⁎Editorials published in JACC: Cardiovascular Imaging reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Imaging or the American College of Cardiology.
Authors: Frederick H. Epstein, Craig H. Meyer
Journal: JACC. Cardiovascular imaging (2011)
Left Main Drug-Eluting Stents: Natural Progression or a Bridge Too Far?⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
Authors: Gregg W. Stone, Jeffrey W. Moses, Martin B. Leon
Journal: Journal of the American College of Cardiology (2007)
Comparison of the current renal staging, progression and response criteria to predict renal survival in <scp>AL</scp> amyloidosis using a <scp>Mayo</scp> cohort
Authors: Maria Eleni Drosou, Lisa E. Vaughan, Eli Muchtar, Francis K. Buadi, David Dingli, Angela Dispenzieri, Amie L. Fonder, Morie A. Gertz, Ronald S. Go, Wilson I. Gonsalves, Suzanne R. Hayman, Miriam A. Hobbs, Yi L. Hwa, Prashant Kapoor, Taxiarchis Kourelis, Shaji Kumar, Robert A. Kyle, Martha Q. Lacy, Yi Lin, Camden L. Lopez, John A. Lust, S. Vincent Rajkumar, Stephen J. Russell, Surbhi Sidana, Mustaqeem A. Siddiqui, M. Hasib Sidiqi, Rahma Warsame, Nelson Leung
Journal: American Journal of Hematology (2021)

Three sets of criteria (International Society of Amyloidosis [ISA], Palladini and Kastritis) were independently developed for staging, progression and response criteria to predict renal survival in patients with AL amyloidosis. We evaluated these criteria using a cohort of 495 newly diagnosed AL amyloidosis patients with renal involvement using time to event competing risk analysis at baseline, 3, 6 and 12 months after treatment. Only Palladini and Kastritis had a staging system and both predicted a higher risk of end stage renal disease (ESRD) in the stage III vs stage I patients but only the Palladini model was predictive for stage II patients. At 3 months, risk of ESRD was significantly higher for Palladini and ISA renal progression (hazard ratio [HR] 2.8 [95% CI: 1.5-5.3, p = .001] and 2.5 [CI: 1.4-4.6, p = .004, respectively]), but renal response was not significantly protective; conversely, the risk of ESRD was not significantly higher for the Kastritis renal progression, but was significantly protective for the Kastritis renal responders (HR 0.38 [95% CI: 0.17-0.84], p = .017). Both progression and response with ISA, Palladini and Kastritis criteria were predictive of ESRD at 6 months and 12 months. While the Palladini staging criteria at baseline, and the ISA and Palladini criteria for progression at 3 months performed better than the Kastritis criteria at baseline and 3 months post-treatment, the Kastritis criteria performed better for response 3 months after treatment. All three sets of criteria performed well at and after 6 months post-treatment. These differences are important when choosing endpoints for clinical trials.
Modernize Medical Licensing, and Credentialing, Too—Lessons From the COVID-19 Pandemic
Authors: Donnie L. Bell, Mitchell H. Katz
Journal: JAMA Internal Medicine (2021)

United States, only 32% of HBV-infected individuals are aware of their disease, and awareness is suboptimal in all risk groups. 16 Public health initiatives to raise awareness of HBV are essential to preventing the spread of infection among high-risk groups, increasing uptake of screening and vaccination, and maximiz-ing the benefit of antiviral therapy.Along those lines, the update to the USPSTF HBV screening guidelines 3 brings HBV back to the forefront for health care professionals, patients, and the general public, and represents an important renewed commitment to the goal of viral hepatitis elimination nationwide.
In situ poly I:C released from living cell drug nanocarriers for macrophage-mediated antitumor immunotherapy
Authors: Haimei Zhou, Huamei He, Ruijing Liang, Hong Pan, Ze Chen, Guanjun Deng, Shengping Zhang, Yifan Ma, Lanlan Liu, Lintao Cai
Journal: Biomaterials (2021)
AB0187 Percutaneous vertebroplasty in rheumatology
Authors: MC García Gómez, C Galisteo, N Navarro, M Castellanos, C Alegre, M Rovira, J Serra, LL Mebarak
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> <h3>Objectives</h3> The percutaneous vertebroplasty (PVP) consists in the percutaneous injection of a biomaterial, plimethylmethacrylate, inside of vertebral body, with the idea of consolidating the vertebral body and to relieve the pain. It is indicated in the treatment of the persistent pain of vertebral body injury, mainly the aggressive hemangioma, the tumoural processes (myeloma and metastasis) and also in the osteoporotic vertebral collapse. We present our experience in this technique. <h3>Methods</h3> We show seven clinical cases, with radiology pictures, about PVP guided by TAC, under local anaesthesia and general sedation, which first indications were to relieve the pain. There are 5 women with an average age of 65 years (40–80) and osteoporotic collapse vertebral. one of them with an hemangioma located in D12 also, a man 72 years old with an hemangioma in L3 and a man 85 years old with a metastasis in L2 secondary to renal tumour. <h3>Results</h3> In the seven cases we got to relieve the pain before, the consolidation of the vertebral body, the reduction of the hospitalisation period and saving to have analgesic drugs. In none of them we had complications, except for a case that we caused leakage of cement into adjacent disks, without secondary effects. In the case of the vertebral metastasis the posterior wall was fractured and pushed in the channel, but we didn´t cause leakage of cement into the channel. <h3>Conclusion</h3> The PVP has been an effective technique in the treatment of the persistent pain in the osteoporotic vertebral collapse, vertebral hemangioma and tumoural process in our patients. It could be an alternative good treatment, and besides it allows an earlier mobilisation, as it prevents the apparition of deformities and possible secundaries complications about this. This is not an expensive procedure, with some possible risk derivated from the technique. Results for long-term follow-up are not yet known and we should make controlled studies to specify which patients could be benefited by technique.
Inflammatory markers, clinical and subclinical cardiovascular disease in older persons: the Health ABC study
Authors: Marco Pahor, Steve B Kritchevsky, Russell P Tracy, Anne B Newman, Kim Sutton-Tyrrell, Luciana Carosella, Graziano Onder, Eleanor M Simonsick, Tamara B Harris, Brenda BWJH Penninx
Journal: Circulation (2001)

P37 Inflammation is a potentially important mechanism underlying cardiovascular disease (CVD). Several studies have assessed the asociations of inflammation with clinical CVD, but data on inflammation and sub-clinical CVD are limited. We assessed the association of C-reactive protein (CRP) and interleukin-6 (IL-6) with clinical and subclinical CVD in the Health and Body Composition study (Health ABC), a cohort study of 3075 well functioning older adults living in Memphis, TN, and Pittsburgh, PA. Mean±SDM age was 73.6±2.9 years, 51.5% were women and 41.7% were African American. History of heart attack, heart failure, stroke, peripheral artery disease or CV procedures was reported by 31.4% of participants. Subclinical disease (positive Rose questionnaire for angina or claudication, ECG abnormalities, or ankle brachial index &lt;0.9 in persons with no clinical CVD) was found in 32.4% of participants. CRP (mean 2.31±3.01 μg/ml, range 0.16-54.03 μg/ml) was measured in 1370 participants, and IL-6 (mean±SDM 2.39±1.92 ng/ml, range 0.21-15.96 ng/ml) was measured in 2824 participants. After adjustment for age, gender, race, site, history of diabetes, smoking status, body-mass index, use of anti-inflammatory drugs and serum cholesterol, HDL cholesterol, creatinine and albumin, higher CRP levels were significantly associated with a higher risk of clincal CVD, but not with risk of subclinical CVD (p for trend with increasing IL-6 tertiles =0.0082 and =0.55)(see Table). Higher IL-6 levels were significantly associated with a higher risk of both clinical and sub-clinical CVD (p for trend with increasing IL-6 tertiles &lt;0.0001 and =0.0003). Table 1.
Heart Failure With Preserved Ejection Fraction: Failure to Preserve, Failure of Reserve, and Failure on the Compliance Curve⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
Authors: Samer S. Najjar
Journal: Journal of the American College of Cardiology (2009)
The State of Melanoma: Emergent Challenges and Opportunities
Authors: Michael B. Atkins, Clara Curiel-Lewandrowski, David E. Fisher, Susan M. Swetter, Hensin Tsao, Julio A. Aguirre-Ghiso, Maria S. Soengas, Ashani T. Weeraratna, Keith T. Flaherty, Meenhard Herlyn, Jeffrey A. Sosman, Hussein A. Tawbi, Anna C. Pavlick, Pamela B. Cassidy, Sunandana Chandra, Paul B. Chapman, Adil Daud, Zeynep Eroglu, Laura K. Ferris, Bernard A. Fox, Jeffrey E. Gershenwald, Geoffrey T. Gibney, Douglas Grossman, Brent A. Hanks, Douglas Hanniford, Eva Hernando, Joanne M. Jeter, Douglas B. Johnson, Samir N. Khleif, John M. Kirkwood, Sancy A. Leachman, Darren Mays, Kelly C. Nelson, Vernon K. Sondak, Ryan J. Sullivan, Glenn Merlino
Journal: Clinical Cancer Research (2021)

Five years ago, the Melanoma Research Foundation (MRF) conducted an assessment of the challenges and opportunities facing the melanoma research community and patients with melanoma. Since then, remarkable progress has been made on both the basic and clinical research fronts. However, the incidence, recurrence, and death rates for melanoma remain unacceptably high and significant challenges remain. Hence, the MRF Scientific Advisory Council and Breakthrough Consortium, a group that includes clinicians and scientists, reconvened to facilitate intensive discussions on thematic areas essential to melanoma researchers and patients alike, prevention, detection, diagnosis, metastatic dormancy and progression, response and resistance to targeted and immune-based therapy, and the clinical consequences of COVID-19 for patients with melanoma and providers. These extensive discussions helped to crystalize our understanding of the challenges and opportunities facing the broader melanoma community today. In this report, we discuss the progress made since the last MRF assessment, comment on what remains to be overcome, and offer recommendations for the best path forward.
Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03)
Authors: Amar Gajjar, Giles W. Robinson, Kyle S. Smith, Tong Lin, Thomas E. Merchant, Murali Chintagumpala, Anita Mahajan, Jack Su, Eric Bouffet, Ute Bartels, Tal Schechter, Tim Hassall, Thomas Robertson, Wayne Nicholls, Sridharan Gururangan, Kristin Schroeder, Michael Sullivan, Greg Wheeler, Jordan R. Hansford, Stewart J. Kellie, Geoffrey McCowage, Richard Cohn, Michael J. Fisher, Matthew J. Krasin, Clinton F. Stewart, Alberto Broniscer, Ivo Buchhalter, Ruth G. Tatevossian, Brent A. Orr, Geoff Neale, Paul Klimo, Frederick Boop, Ashok Srinivasan, Stefan M. Pfister, Richard J. Gilbertson, Arzu Onar-Thomas, David W. Ellison, Paul A. Northcott
Journal: Journal of Clinical Oncology (2021)

SJMB03 (ClinicalTrials.gov identifier: NCT00085202) was a phase III risk-adapted trial that aimed to determine the frequency and clinical significance of biological variants and genetic alterations in medulloblastoma.
Abstract 11806: The Modulating Effect of Exercise on Heart Rate Variability After Bariatric Surgery
Authors: David Belzile, Alexane Lebel, Audrey Auclair, Myriam Pettigrew, Laurent Biertho, Simon Marceau, Paul Poirier
Journal: Circulation (2019)

Introduction: Heart rate variability (HRV) is a recognized cardiovascular prognostic factor as reduced HRV is associated with adverse cardiovascular events. Interestingly, studies have demonstrated...
Revisiting the global workspace orchestrating the hierarchical organization of the human brain
Authors: Gustavo Deco, Diego Vidaurre, Morten L. Kringelbach
Journal: Nature Human Behaviour (2021)

Abstract A central challenge in neuroscience is how the brain organizes the information necessary to orchestrate behaviour. Arguably, this whole-brain orchestration is carried out by a core subset of integrative brain regions, a ‘global workspace’, but its constitutive regions remain unclear. We quantified the global workspace as the common regions across seven tasks as well as rest, in a common ‘functional rich club’. To identify this functional rich club, we determined the information flow between brain regions by means of a normalized directed transfer entropy framework applied to multimodal neuroimaging data from 1,003 healthy participants and validated in participants with retest data. This revealed a set of regions orchestrating information from perceptual, long-term memory, evaluative and attentional systems. We confirmed the causal significance and robustness of our results by systematically lesioning a generative whole-brain model. Overall, this framework describes a complex choreography of the functional hierarchical organization of the human brain.
Annals Graphic Medicine - The Howling: A Tale of Dementia
Authors: Preeyal M. Patel
Journal: Annals of Internal Medicine (2021)

Web ExclusivesJanuary 2021Annals Graphic Medicine - The Howling: A Tale of DementiaFREEPreeyal M. Patel, BSPreeyal M. Patel, BSThomas Jefferson University, Philadelphia, Pennsylvania (P.M.P.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/G20-0036 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Panel 1 Download figure Download PowerPoint Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Thomas Jefferson University, Philadelphia, Pennsylvania (P.M.P.)Disclosures: The author has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=G20-0036.Author/Illustrator Information: Preeyal M. Patel, BS, is a third-year medical student attending Sidney Kimmel Medical College at Thomas Jefferson University in Philadelphia, Pennsylvania. She enjoys exploring how art can portray patient–provider experiences.This article was published at Annals.org on 12 January 2021. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics January 2021Volume 174, Issue 1Page: W15-W16 ePublished: 12 January 2021 Issue Published: January 2021 Copyright & PermissionsCopyright © 2021 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...